Drug Delivery: Injection Devices

Despite its relative invasiveness and technological maturity, instrument-based injection of pharmaceutical preparations is commonly regarded as the most accurate, effective, reliable, and reproducible method of therapeutic drug and fluid delivery. In 2021, combined sales of the injection devices covered by this report totaled nearly $5.7bn. Market drivers include legislative changes requiring the use of safety devices to help prevent needlestick injury, continuing growth in the volume of outpatient infusion procedures relying on more costly longer-term VADs, and an ongoing transition to premium-priced safety catheters in hospitals and alternate care facilities. Market limiters include the development of drug delivery methods that do not involve skin puncture (eg inhalation therapy products, oral medications, and transdermal patches). This analysis includes a discussion of products, current/forecast markets, competitors, and opportunities in the global markets for injection-based drug delivery devices; these include standard and safety needles/syringes, and vascular access devices (short peripheral catheters, midline catheters, PICCs, CVCs, and implantable ports). Countries covered by this report include the US, five major European markets (France, Germany, Italy, Spain, and the UK), Japan, and the Rest of World. The forecast range for this report is 2021–26. 

If you are not a subscriber to Meddevicetracker and would like to purchase this report, please send an email to [email protected]. If you would like more information about obtaining a subscription to the Meddevicetracker database and report library, please send an email to [email protected].